Cambrex to scale up its solid form screening and crystallization process development facility in Edinburgh to answer market demand for larger scale crystallization.
Novartis initiates a recall of Promacta after its contract manufacturer introduced peanut flour into the same facility as the treatment, potentially causing cross-contamination.
Cambrex completes expansion of its R&D laboratory at its Milan site and adds a 12,000-liter reactor to its manufacturing facility during a $3m investment.
Cambrex is investing $1m at its High Point, NC-based site, marking the most recent in a series of investments which will see the addition of 1,300 square feet and 15 new employees.
An API facility Cambrex is setting up in Charles City, Iowa will be operational later than planned due to delayed equipment deliveries and installation challenges.
Ongoing demand for large-scale APIs combined with high capacity utilization has driven Cambrex Corporation to allot up to $85m (€70m) for manufacturing expansion in 2015.
Cambrex reported a dip in revenues in 2009, citing the timing of orders throughout the year, and warned that smaller clients’ funding difficulties and pricing pressures will continue in 2010.
Cambrex has posted a positive set of Q2 results, recording an operating income of $9m (€6.3m), but warned that the second half of the year is likely to be down on the corresponding six months of last year.
Cambrex posted a 5 per cent hike in revenues in the second quarter, helped by its shift into contract controlled substance manufacture, although without favourable currency effects sales would have slipped back 2.6 per cent.
Cambrex has experienced a jump in profitability for the first
quarter 2008, despite a decrease in sales, assisted by previous
cost-cutting initiatives.
Cambrex Corp, the US-based manufacturer of small-molecule active
pharmaceutical ingredients (APIs) and advanced intermediates for
the drug industry, has announced that one of its customers is
recalling a product for which Cambrex...
Cambrex' cost cutting resolve is starting to pay off for the firm,
who achieved an improved profitability in the fourth quarter of
2007, although sales are still stagnant.
Life sciences firm Cambrex has reported a $140.3m (€116.7m) loss in
Q4 as opposed to a profit of $4.9m in Q4 last year, hit by lower
long-term profitability projections for its Biopharma unit, as
biotech companies seem to lose their...
Cambrex has recorded a gain in the third quarter of this year, with
growth in its Bioproducts and Human Health segments. The company's
troublesome BioPharma division continues to underperform,
indicative of a market for outsourced...
Drug discovery company Cambrex' intention to enter a key segment of
the drug discovery arena was substantiated by its purchase of
immortalised cell lines, related technology and equipment.
Cambrex has signed an exclusive license agreement that allows
access to two novel, quantitative assay technologies for the
detection of contaminants such as pathogens in drugs.
Cambrex has initiated a project aimed at constructing a new
facility to accommodate four cGMP-compliant suites dedicated to
cell therapy manufacturing. The company said the expansion would
increase its manufacturing capacity by 100...
